Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × belzutifan × Tumor-Agnostic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5 Endocrine 2 CNS 2 Tumor-Agnostic 1 Gynecologic 1 Breast 1

Conditions

Interventions

Paclitaxel 23 Gemcitabine 22 pembrolizumab 21 Carboplatin 21 Radiotherapy 14 Oxaliplatin 14 Cisplatin 14 Bevacizumab 14 Nivolumab 13 Erlotinib Hydrochloride 13 Fluorouracil 12 Capecitabine 12 Trastuzumab 11 Magnetic Resonance Spectroscopy 10 Leucovorin 10 Docetaxel 10 atezolizumab 9 Irinotecan 9 Everolimus 9 Vemurafenib 8 Ipilimumab 8 Cyclophosphamide 8 130-nm albumin-bound paclitaxel 8 Specimen Handling 7 Radiosurgery 7 Albumin-Bound Paclitaxel 7 Afatinib 7 lenvatinib 6 durvalumab 6 cabozantinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡